CEL-SCI Corporation (CVM)
NYSEAMERICAN: CVM · Real-Time Price · USD
6.85
+0.56 (8.90%)
At close: Jul 24, 2025, 4:00 PM
6.85
0.00 (0.00%)
After-hours: Jul 24, 2025, 8:00 PM EDT

Company Description

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States.

The company’s lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.

It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis.

In addition, the company’s LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments.

CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer.

CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

CEL-SCI Corporation
CEL-SCI logo
CountryUnited States
Founded1983
IPO DateJan 1, 1987
IndustryBiotechnology
SectorHealthcare
Employees43
CEOGeert Kersten

Contact Details

Address:
8229 Boone Boulevard, Suite 802
Vienna, Virginia 22182
United States
Phone703 506 9460
Websitecel-sci.com

Stock Details

Ticker SymbolCVM
ExchangeNYSEAMERICAN
Stock TypeCommon Stock
Fiscal YearOctober - September
Reporting CurrencyUSD
CIK Code0000725363
CUSIP Number150837607
ISIN NumberUS1508376076
Employer ID84-0916344
SIC Code2836

Key Executives

NamePosition
Geert R. Kersten Esq.Chief Executive and Financial Officer, Treasurer and Director
Patricia B. PrichepChief Financial and Operations Officer, Compliance Officer & Corporate Secretary
Dr. Eyal Talor Ph.D.Chief Scientific Officer
Dr. Daniel H. Zimmerman Ph.D.Senior Vice President of Research and Cellular Immunology
John CiprianoSenior Vice President of Regulatory Affairs
Dr. Giovanni Selvaggi M.D.Acting Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Jul 14, 20258-KCurrent Report
Jul 14, 2025424B5Filing
Jul 3, 2025S-3Registration statement under Securities Act of 1933
May 23, 20258-KCurrent Report
May 22, 2025424B5Filing
May 21, 2025424B5Filing
May 19, 20258-KCurrent Report
May 14, 202510-QQuarterly Report
Apr 9, 2025ARSFiling
Apr 9, 2025DEF 14AOther definitive proxy statements